tiprankstipranks
Advertisement
Advertisement

PTGX Stock Latest News

Protagonist Therapeutics Stockholders Approve Directors and Incentive Plan
Company AnnouncementsProtagonist Therapeutics Stockholders Approve Directors and Incentive Plan
16d ago
8K
PTGX
Protagonist Therapeutics price target raised to $130 from $125 at Citi
PremiumThe Fly
Protagonist Therapeutics price target raised to $130 from $125 at Citi
2M ago
PTGX
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
PremiumThe Fly
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
2M ago
PTGX
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
PremiumThe Fly
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
2M ago
PTGX
Protagonist Therapeutics management to meet virtually with Clear Street
PremiumThe Fly
Protagonist Therapeutics management to meet virtually with Clear Street
2M ago
PTGX
Protagonist Therapeutics participates in a conference call with JPMorgan
PremiumThe FlyProtagonist Therapeutics participates in a conference call with JPMorgan
2M ago
PTGX
Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
Premium
The Fly
Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
2M ago
TAK
PTGX
Protagonist Therapeutics price target raised to $121 from $110 at Truist
Premium
The Fly
Protagonist Therapeutics price target raised to $121 from $110 at Truist
3M ago
JNJ
PTGX
Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target
PremiumRatings
Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target
3M ago
PTGX
Protagonist Therapeutics price target raised to $121 from $110 at Truist
PremiumThe Fly
Protagonist Therapeutics price target raised to $121 from $110 at Truist
3M ago
JNJ
PTGX
Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
PremiumThe Fly
Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
3M ago
PTGX
Protagonist price target raised to $110 from $107 at Leerink
PremiumThe Fly
Protagonist price target raised to $110 from $107 at Leerink
4M ago
PTGX
Protagonist Therapeutics price target raised to $120 from $112 at Citizens
PremiumThe FlyProtagonist Therapeutics price target raised to $120 from $112 at Citizens
4M ago
PTGX
Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
Premium
The Fly
Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
4M ago
PTGX
Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
Premium
The Fly
Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
4M ago
PTGX
Protagonist Therapeutics price target raised to $125 from $115 at Citi
PremiumThe Fly
Protagonist Therapeutics price target raised to $125 from $115 at Citi
4M ago
PTGX
Protagonist Therapeutics price target raised to $119 from $113 at Barclays
PremiumThe Fly
Protagonist Therapeutics price target raised to $119 from $113 at Barclays
4M ago
PTGX
Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
PremiumThe Fly
Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
4M ago
PTGX
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
PremiumRatings
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
4M ago
PTGX
Icotyde label upside surprise for Protagonist, says H.C. Wainwright
PremiumThe FlyIcotyde label upside surprise for Protagonist, says H.C. Wainwright
4M ago
JNJ
PTGX
Protagonist announces Johnson & Johnson received approval for ICOTYDE
Premium
The Fly
Protagonist announces Johnson & Johnson received approval for ICOTYDE
4M ago
JNJ
PTGX
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
Premium
TipRanks Newswire
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
4M ago
AZN
IBO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >